TriSalus Life Sciences (TLSI) Q3 2026 earnings review
TriSalus cuts 2026 sales plan, though Medicare raises 2027 rates
TriSalus Life Sciences, the maker of the TriNav catheter for delivering cancer drugs into solid tumors, won major regulatory approvals for 2027 but cut its 2026 sales plan again. Third-quarter revenue rose 11% from a year ago to $12.9 million. Because newly hired sales reps took longer to win business than chief executive Mary Szela anticipated, the company lowered its full-year revenue outlook to $46 million to $48 million, which by our math leaves fourth-quarter sales up less than 5% from a year ago.
| Revenue | $12.9M +11.3% from a year ago |
|---|---|
| Gross margin | 86.2% +2.6 percentage points from a year ago |
| Full-year 2026 revenue outlook | Cut $8.5M middle of the range: $47M (+4.1% growth) |
| 2027 Medicare C8004 hospital rate | $20,910 +77% from the 2026 rate of $11,794 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the second outlook cut in three quarters removes the second-half sales jump the business was built to deliver. By our math, both third-quarter trailing sales of $46 million and the new full-year target fall short of the $49 million and $50 million revenue thresholds in the OrbiMed loan agreement. The good news: regulators cleared the delayed TriNav Advance catheter and Medicare finalized a 77% hospital rate increase alongside a new $13,800 office payment for 2027.
The question now is whether the 2026 slowdown is only a delayed ramp for new sales reps or proof that hospital demand leveled off once last year's billing code passed its one-year mark. If new reps plus the 2027 Medicare rate increases drive demand, growth will rebound sharply next year; if the core liver market is saturated, the doubled sales payroll will keep burning cash. The third-quarter 10-Q debt footnote and initial 2027 revenue outlook will tell.
🐂 Bull Case
Medicare Finalizes Higher 2027 Hospital and Office Rates
TriSalus sells the TriNav catheter system, which uses pressure to push cancer drugs deeper into solid tumors. Because the oncology group sells one main device line, its sales depend on what the Centers for Medicare and Medicaid Services (CMS), the federal health agency, pays doctors and hospitals. Until now, final payment rates for physician office clinics were a standing risk because the agency had not set them.
This quarter CMS finalized its 2027 rules and raised both hospital and office rates starting January 1, 2027. For hospital outpatient mapping procedures billed under code C8004, the national Medicare payment jumps 77% by our math, from about $11,794 to about $20,910. The agency also set a national payment of about $13,800 per procedure for code G0577, covering "vascular embolization using a pressure-generating catheter in the office-based lab setting".
The two final rules remove the pricing uncertainty around the office expansion and raise hospital Economics for mapping procedures before treatment. What to watch: the initial 2027 revenue outlook in next quarter's release. A double-digit growth target would show that the new Medicare rates are bringing in office accounts and boosting hospital orders.
FDA Clears Delayed TriNav Advance Catheter
Management had promised a smaller version of its catheter, called TriNav Advance, for late 2025 and then the first half of 2026. Regulatory delays held the launch back and contributed to the first outlook cut earlier this year. In the third quarter, the Food and Drug Administration cleared the device.
Chief executive Mary Szela said the new product "enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice". That matters because doctors can now use TriSalus technology in smaller blood vessels without giving up their preferred steering tube, letting the medical device maker "address the full range of vessels encountered in liver embolization procedures going forward", Szela said. Separately, the PROTECT registry studying thyroid artery procedures hit its enrollment goal, keeping the firm on track to "deliver the first multi-center U.S. data on thyroid artery embolization in the first quarter of 2027".
What to watch: fourth-quarter revenue, which the new full-year plan puts at $13.8 million at the middle of the range by our math, up 4.6% from a year ago. Beating that figure would show that TriNav Advance is adding sales right away rather than just replacing the older catheter.
Lower Unit Costs Lift Gross Margin
Last year, launching new catheter sizes hurt factory efficiency and pulled gross margin down to 83.5% in the third quarter of 2025. Production has now settled down. Gross margin rose 2.6 percentage points from a year ago to 86.2%, as cost of goods sold — the direct cost of making the catheters — fell from 16.5% of revenue to 13.8%.
The company said the gain came from a "reduction in cost per TriNav unit". Keeping gross margin above 86% means almost 86 cents of every new sales dollar goes toward covering overhead. What to watch: fourth-quarter gross margin as TriNav Advance production ramps up. Holding the 86% level would show the factory can add a new product line without repeating last year's cost dip.
🐻 Bear Case
Slow Sales Ramp Forces Second Outlook Cut
TriSalus more than doubled its sales team in the first half of 2026 and kept its $54 million to $57 million full-year revenue target intact just three months ago. This quarter, Szela said "our team productivity has ramped slightly slower than anticipated", and the company cut its 2026 sales plan to $46 million to $48 million.
- Third-quarter revenue: $12.9 million, up 11.3% from a year ago against a 57.4% jump in the prior year
- Full-year revenue outlook: cut by $8.5 million at the middle of the range, following a $5.5 million cut in the first quarter
- Implied fourth-quarter revenue: $12.8 million to $14.8 million by our math, or 4.6% growth from a year ago at the middle of the range
- Implied second-half revenue: $25.7 million to $27.7 million by our math, down 24.2% from what the prior outlook required
Calling the sales ramp only slightly slower does not match an $8.5 million cut with one quarter left in the year. The new outlook points to fourth-quarter sales growing less than 5% from a year ago, showing that once the 2025 hospital billing boost passed its one-year mark, the larger sales force did not generate the promised second-half jump. What to watch: whether fourth-quarter sales top $14.8 million, the top of the implied range. Falling inside or below it would confirm that new reps take longer than six to nine months to pay for themselves.
Sales Miss Leaves Revenue Below Loan Thresholds
Under its loan agreement with lender OrbiMed, TriSalus must meet trailing twelve-month revenue targets at the end of each quarter or begin paying back the roughly $35 million principal in monthly installments through April 2029. After the company lowered those targets twice in the spring, the agreement required $48.75 million of trailing sales on September 30 and $50.0 million on December 31.
By our math, third-quarter revenue of $12.9 million puts trailing twelve-month sales at $46.4 million, which is $2.4 million short of the September 30 requirement. The new full-year outlook of $46 million to $48 million also sits entirely below the $50.0 million year-end requirement. The earnings release does not mention a loan waiver or amendment, and the balance sheet still lists $32.4 million as long-term debt with zero current debt.
Keeping the loan in long-term liabilities suggests the company either secured another waiver or expects to, though it also had to revise prior-year research and overhead classifications in this release. What to watch: the debt footnote in the third-quarter 10-Q filing. Without a waiver lowering the targets below $46 million, monthly principal payments of more than $1.1 million by our math would add directly to cash burn.
Doubled Sales Force Keeps Cash Burn High
Expanding the commercial team has lifted fixed costs much faster than sales. Sales and marketing spending — salaries, commissions and marketing programs — rose 56.9% from a year ago to $10.7 million, climbing by 24.2 percentage points of revenue to consume 83.3% of everything the company sold.
Operating loss narrowed from $9.0 million a year ago to $7.7 million only because research and development fell by 24.6 percentage points of revenue (after clinical trials wound down) and general overhead fell by 15.1 points. Even so, free cash flow was negative $5.4 million in the quarter by our math, pulling cash down by $5.2 million from June to $41.1 million. What to watch: sales and marketing expense in the fourth quarter. If commercial spending stays near $11 million while revenue sits near $14 million, the company will keep burning over $5 million a quarter.
💲 Other KPIs
Up 35.8% from 43.1 million shares a year ago, and steady against 58.3 million in the second quarter. The share count climbed over the past year because the oncology group converted preferred stock into common shares in late 2025 and sold $46 million of new stock in early 2026 to fund its sales expansion.
Both working-capital lines grew much faster than the 11.3% rise in revenue. Net inventory rose 41.6% from a year ago (and 50.7% since December) to $4.6 million as the firm stocked new catheter versions, tying up $1.6 million of cash this year. Accounts receivable — bills customers have not yet paid — rose 22.5% from a year ago to $6.1 million.
The loss excluding interest, taxes, depreciation, stock compensation and non-cash liability revaluations narrowed from $5.4 million a year ago and $7.1 million in the second quarter. Sequential improvement came from the $1.5 million rise in quarterly sales and a $0.7 million drop in sales and marketing costs after second-quarter hiring finished.
🔮 Guidance
Cut. The middle of the range fell by $8.5 million, reducing planned full-year growth from 23% to about 4.1% by our math. That leaves $12.8 million to $14.8 million for the fourth quarter, or 4.6% growth from a year ago at the middle of the range, down from 11.3% in Q3. It is the second cut in three quarters: -$5.5M in Q1, held in Q2, and -$8.5M now.
❓ Key Questions
Did OrbiMed waive or lower the September and December revenue covenants?
Trailing twelve-month revenue of $46.4 million missed the $48.75 million September 30 loan threshold, and the $46 million to $48 million full-year plan sits below the $50.0 million December 31 threshold. Investors need the terms and fees of any sixth loan amendment.
Why does the outlook imply fourth-quarter growth slowing to 5%?
By our math, the middle of the new full-year range points to $13.8 million in fourth-quarter sales, up just 4.6% from a year ago and less than $1 million above the third quarter, even with TriNav Advance now cleared.
How many ordering accounts and sales reps are active today?
Management stopped reporting unique ordering hospitals and exact sales headcount after mid-2025. Without those figures, outside investors cannot tell whether slow revenue comes from fewer new hospital accounts or lower catheter use per doctor.
When will TriSalus release the consolidated nelitolimod Phase 1 data?
The company previously targeted the second half of 2026 for a combined data readout to attract a drug partner, but the press release repeats only that it is in the final stages of data completion.